PT  - JOURNAL ARTICLE
AU  - Wang, Authors: Shuo
AU  - Rao, Zexi
AU  - Cao, Rui
AU  - Blaes, Anne H.
AU  - Coresh, Josef
AU  - Joshu, Corinne E.
AU  - Lehallier, Benoit
AU  - Lutsey, Pamela L.
AU  - Pankow, James S.
AU  - Sedaghat, Sanaz
AU  - Tang, Weihong
AU  - Thyagarajan, Bharat
AU  - Walker, Keenan A.
AU  - Ganz, Peter
AU  - Platz, Elizabeth A.
AU  - Guan, Weihua
AU  - Prizment, Anna
TI  - Development and Characterization of Proteomic Aging Clocks in the Atherosclerosis Risk in Communities (ARIC) Study
AID  - 10.1101/2023.09.06.23295174
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.06.23295174
4099  - http://medrxiv.org/content/early/2023/09/08/2023.09.06.23295174.short
4100  - http://medrxiv.org/content/early/2023/09/08/2023.09.06.23295174.full
AB  - Biological age may be estimated by proteomic aging clocks (PACs). Previous published PACs were constructed either in smaller studies or mainly in White individuals, and they used proteomic measures from only one-time point. In the Atherosclerosis Risk in Communities (ARIC) study of about 12,000 persons followed for 30 years (around 75% White, 25% Black), we created de novo PACs and compared their performance to published PACs at two different time points. We measured 4,712 plasma proteins by SomaScan in 11,761 midlife participants, aged 46-70 years (1990-92), and 5,183 late-life pariticpants, aged 66-90 years (2011-13). All proteins were log2-transformed to correct for skewness. We created de novo PACs by training them against chronological age using elastic net regression in two-thirds of healthy participants in midlife and late life and compared their performance to three published PACs. We estimated age acceleration (by regressing each PAC on chronological age) and its change from midlife to late life. We examined their associations with mortality from all-cause, cardiovascular disease (CVD), cancer, and lower respiratory disease (LRD) using Cox proportional hazards regression in all remaining participants irrespective of health. The model was adjusted for chronological age, smoking, body mass index (BMI), and other confounders. The ARIC PACs had a slightly stronger correlation with chronological age than published PACs in healthy participants at each time point. Associations with mortality were similar for the ARIC and published PACs. For late-life and midlife age acceleration for the ARIC PACs, respectively, hazard ratios (HRs) per one standard deviation were 1.65 and 1.38 (both p<0.001) for all-cause mortality, 1.37 and 1.20 (both p<0.001) for CVD mortality, 1.21 (p=0.03) and 1.04 (p=0.19) for cancer mortality, and 1.46 and 1.68 (both p<0.001) for LRD mortality. For the change in age acceleration, HRs for all-cause, CVD, and LRD mortality were comparable to those observed for late-life age acceleration. The association between the change in age acceleration and cancer mortality was insignificant. In this prospective study, the ARIC and published PACs were similarly associated with an increased risk of mortality and advanced testing in relation to various age-related conditions in future studies is suggested.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAP - R01CA267977 (https://www.nih.gov/) AP and SS - R21AG079242 (https://www.nih.gov/) ARIC has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services, under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, 75N92022D00005). This work was supported in part by NIH/NHLBI grant R01 HL134320. Cancer data in ARIC are also supported by the National Cancer Institute (U01 CA164975 and NU58DP007114).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ARIC study was approved by institutional review boards at each participating center and all study participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesARIC data can be accessed via BioLINCC (https://biolincc.nhlbi.nih.gov/studies/aric/) free of charge and without the need for the ARIC Study approval (accession number: HLB00020023a).